-
1
-
-
5344233478
-
Pulmonary arterial hypertension
-
Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-65.
-
(2004)
N Engl J Med
, vol.351
, pp. 1655-1665
-
-
Farber, H.W.1
Loscalzo, J.2
-
2
-
-
67649579669
-
Updated clinical classification of pulmonary hypertension
-
Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54.
-
(2009)
J am Coll Cardiol
, vol.54
, pp. S43-S54
-
-
Simonneau, G.1
Robbins, I.M.2
Beghetti, M.3
Channick, R.N.4
Delcroix, M.5
Denton, C.P.6
-
3
-
-
67649588196
-
Updated evidence-based treatment algorithm in pulmonary arterial hypertension
-
Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S78-84.
-
(2009)
J am Coll Cardiol
, vol.54
, pp. S78-S84
-
-
Barst, R.J.1
Gibbs, J.S.2
Ghofrani, H.A.3
Hoeper, M.M.4
McLaughlin, V.V.5
Rubin, L.J.6
-
4
-
-
64849109410
-
ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association
-
McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-619.
-
(2009)
J am Coll Cardiol
, vol.53
, pp. 1573-1619
-
-
McLaughlin, V.V.1
Archer, S.L.2
Badesch, D.B.3
Barst, R.J.4
Farber, H.W.5
Lindner, J.R.6
-
5
-
-
3142726157
-
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
-
Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:35S-62S.
-
(2004)
Chest
, vol.126
, pp. 35S-62S
-
-
Badesch, D.B.1
Abman, S.H.2
Ahearn, G.S.3
Barst, R.J.4
McCrory, D.C.5
Simonneau, G.6
-
6
-
-
77349113347
-
Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension
-
Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med 2010;104:481-96.
-
(2010)
Respir Med
, vol.104
, pp. 481-496
-
-
Tonelli, A.R.1
Alnuaimat, H.2
Mubarak, K.3
-
7
-
-
0026632785
-
The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
-
Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
-
(1992)
N Engl J Med
, vol.327
, pp. 76-81
-
-
Rich, S.1
Kaufmann, E.2
Levy, P.S.3
-
8
-
-
20544448927
-
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension
-
Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11.
-
(2005)
Circulation
, vol.111
, pp. 3105-3111
-
-
Sitbon, O.1
Humbert, M.2
Jais, X.3
Ioos, V.4
Hamid, A.M.5
Provencher, S.6
-
9
-
-
0031869664
-
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
-
Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998;12:265-70.
-
(1998)
Eur Respir J
, vol.12
, pp. 265-270
-
-
Sitbon, O.1
Humbert, M.2
Jagot, J.L.3
Taravella, O.4
Fartoukh, M.5
Parent, F.6
-
10
-
-
0025837793
-
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry
-
D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Internal Med 1991;115:343-9.
-
(1991)
Ann Internal Med
, vol.115
, pp. 343-349
-
-
D’Alonzo, G.E.1
Barst, R.J.2
Ayres, S.M.3
Bergofsky, E.H.4
Brundage, B.H.5
Detre, K.M.6
-
11
-
-
0037126044
-
Survival in primary pulmonary hypertension: The impact of epoprostenol therapy
-
McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002;106:1477-82.
-
(2002)
Circulation
, vol.106
, pp. 1477-1482
-
-
McLaughlin, V.V.1
Shillington, A.2
Rich, S.3
-
12
-
-
10044258461
-
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology
-
Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-78.
-
(2004)
Eur Heart J
, vol.25
, pp. 2243-2278
-
-
Galie, N.1
Torbicki, A.2
Barst, R.3
Dartevelle, P.4
Haworth, S.5
Higenbottam, T.6
-
13
-
-
0032576672
-
Reduction in pulmonary vascular resistance with long-term epoprostenol (Prostacyclin) therapy in primary pulmonary hypertension
-
McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
-
(1998)
N Engl J Med
, vol.338
, pp. 273-277
-
-
McLaughlin, V.V.1
Genthner, D.E.2
Panella, M.M.3
Rich, S.4
-
14
-
-
1342288852
-
Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension
-
Morales-Blanhir J, Santos S, de Jover L, Sala E, Paré C, Roca J, et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 2004;98:225-34.
-
(2004)
Respir Med
, vol.98
, pp. 225-234
-
-
Morales-Blanhir, J.1
Santos, S.2
De Jover, L.3
Sala, E.4
Paré, C.5
Roca, J.6
-
15
-
-
0032190635
-
Inhaled nitric oxide in primary pulmonary hypertension: A safe and effective agent for predicting response to nifedipine
-
Ricciardi MJ, Knight BP, Martinez FJ, Rubenfire M. Inhaled nitric oxide in primary pulmonary hypertension: A safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 1998;32:1068-73.
-
(1998)
J am Coll Cardiol
, vol.32
, pp. 1068-1073
-
-
Ricciardi, M.J.1
Knight, B.P.2
Martinez, F.J.3
Rubenfire, M.4
-
16
-
-
0028888649
-
Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin
-
Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995;151:384-9.
-
(1995)
Am J Respir Crit Care Med
, vol.151
, pp. 384-389
-
-
Sitbon, O.1
Brenot, F.2
Denjean, A.3
Bergeron, A.4
Parent, F.5
Azarian, R.6
-
17
-
-
77951961897
-
Survival in pulmonary arterial hypertension: A reappraisal of the NIH risk stratification equation
-
Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: A reappraisal of the NIH risk stratification equation. Eur Respir J;35:1079-87.
-
Eur Respir J
, vol.35
, pp. 1079-1087
-
-
Thenappan, T.1
Shah, S.J.2
Rich, S.3
Tian, L.4
Archer, S.L.5
Gomberg-Maitland, M.6
-
18
-
-
77954759389
-
Predicting survival in pulmonary arterial hypertension: Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)
-
Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164-72.
-
(2010)
Circulation
, vol.122
, pp. 164-172
-
-
Benza, R.L.1
Miller, D.P.2
Gomberg-Maitland, M.3
Frantz, R.P.4
Foreman, A.J.5
Coffey, C.S.6
-
19
-
-
0021828193
-
The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension
-
Rich S, Brundage BH, Levy PS. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. Circulation 1985;71:1191-6.
-
(1985)
Circulation
, vol.71
, pp. 1191-1196
-
-
Rich, S.1
Brundage, B.H.2
Levy, P.S.3
-
20
-
-
69249119028
-
Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension
-
Jing ZC, Jiang X, Han ZY, Xu XQ, Wang Y, Wu Y, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 2009;33:1354-60.
-
(2009)
Eur Respir J
, vol.33
, pp. 1354-1360
-
-
Jing, Z.C.1
Jiang, X.2
Han, Z.Y.3
Xu, X.Q.4
Wang, Y.5
Wu, Y.6
-
21
-
-
0030024879
-
Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension
-
Raffy O, Azarian R, Brenot F, Parent F, Sitbon O, Petitpretz P, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996;93:484-8.
-
(1996)
Circulation
, vol.93
, pp. 484-488
-
-
Raffy, O.1
Azarian, R.2
Brenot, F.3
Parent, F.4
Sitbon, O.5
Petitpretz, P.6
-
22
-
-
0023615359
-
Primary pulmonary hypertension. A national prospective study
-
Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension. A national prospective study. Ann Internal Med 1987;107:216-23.
-
(1987)
Ann Internal Med
, vol.107
, pp. 216-223
-
-
Rich, S.1
Dantzker, D.R.2
Ayres, S.M.3
Bergofsky, E.H.4
Brundage, B.H.5
Detre, K.M.6
-
23
-
-
62249199804
-
Treatment and survival in children with pulmonary arterial hypertension: The UK Pulmonary Hypertension Service for Children 2001-2006
-
Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart 2009;95:312-7.
-
(2009)
Heart
, vol.95
, pp. 312-317
-
-
Haworth, S.G.1
Hislop, A.A.2
-
24
-
-
0033662278
-
Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology
-
Krasuski RA, Warner JJ, Wang A, Harrison JK, Tapson VF, Bashore TM. Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. J Am Coll Cardiol 2000;36:2204-11.
-
(2000)
J am Coll Cardiol
, vol.36
, pp. 2204-2211
-
-
Krasuski, R.A.1
Warner, J.J.2
Wang, A.3
Harrison, J.K.4
Tapson, V.F.5
Bashore, T.M.6
-
25
-
-
0033782458
-
Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension
-
Strange C, Bolster M, Mazur J, Taylor M, Gossage JR, Silver R. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest 2000;118:1077-82.
-
(2000)
Chest
, vol.118
, pp. 1077-1082
-
-
Strange, C.1
Bolster, M.2
Mazur, J.3
Taylor, M.4
Gossage, J.R.5
Silver, R.6
-
26
-
-
0028070791
-
Hemodynamic effects of inhaled nitric oxide in heart failure
-
Semigran MJ, Cockrill BA, Kacmarek R, Thompson BT, Zapol WM, Dec GW, et al. Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol 1994;24:982-8.
-
(1994)
J am Coll Cardiol
, vol.24
, pp. 982-988
-
-
Semigran, M.J.1
Cockrill, B.A.2
Kacmarek, R.3
Thompson, B.T.4
Zapol, W.M.5
Dec, G.W.6
|